Journal
FUTURE ONCOLOGY
Volume 8, Issue 3, Pages 321-331Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/FON.12.3
Keywords
bone metastases; circulating tumor cells; metastatic prostate cancer; prostate cancer; prostate-specific antigen
Categories
Funding
- Veridex
- Novartis Pharmaceuticals
Ask authors/readers for more resources
Prostate-specific antigen (PSA) has been used for over two decades as a serum marker for adenocarcinoma of the prostate. Although PSA screening remains an important part of disease screening and monitoring in early prostate cancer (PC), its utility in monitoring disease progression in advanced PC is undetermined. Furthermore, the role of PSA monitoring in the management of patients with PC and bone metastases appears limited. The purpose of this review is to evaluate the role of circulating tumor cells (CTCs) as potential novel biomarkers in advanced PC. We present a review of CTC testing and the clinical data supporting the prognostic potential of CTCs in this setting. We propose that combination of CTCs and PSA velocity or doubling-time assessments may offer insights into the prognosis and management of advanced PC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available